Key result
Cranial irradiation plus chemotherapy linked to ~175% higher dysmetabolic syndrome prevalence in childhood ALL survivors.
Why the study?
Early indicators of dysmetabolic syndrome in young survivors of childhood acute lymphoblastic leukemia were investigated to identify risk factors for metabolic complications.
Does cranial irradiation in addition to chemotherapy increase the risk of dysmetabolic syndrome in young survivors of childhood ALL?
Observational (n=80)
Does cranial irradiation in addition to chemotherapy increase the risk of dysmetabolic syndrome in young survivors of childhood ALL?
Young survivors of childhood ALL, particularly those treated with cranial irradiation, have a significantly increased risk of developing dysmetabolic syndrome early after therapy completion.
Answers are grounded in this paper and cite their sources.
Supports enhanced metabolic surveillance in irradiated ALL survivors; leaves open causality and requires prospective confirmation.
PURPOSE: To investigate the presence of early indicators of the dysmetabolic syndrome (DS) in young survivors with acute lymphoblastic leukemia (ALL) in childhood. PATIENTS AND METHODS: We enrolled 80 patients with ALL (50 males, median age 13.9 y, median interval since completion of chemotherapy 6.3 y). Sixty-two patients (group A) received chemotherapy only, whereas 18 patients (group B) received chemotherapy and cranial irradiation (18 Gy). RESULTS: Frank obesity [25%; confidence interval (CI) 95%, 16.7%-35.6%], increased blood pressure (21%; CI 95%, 13.6%-31.5%), increased serum triglycerides (21%; CI 95%, 13.6%-31.5%), reduced serum high-density lipoprotein cholesterol (12%; CI 95%, 6.7%-21.7%), increased fasting insulin (8%; CI 95%, 3.2%-15.7%), and osteopenia (71%; CI 95%, 60.5%-80.1%) were detected in groups A and B. Reduced IGF-1 (15%; CI 95%, 8.6%-24.6%) and thyroid hormone abnormalities (11%; CI 95%, 5.8%-20.2%) were detected only in group B. In group B, there was a statistically significant increase in the prevalence of obesity (P=0.024), hyperinsulinemia (P=0.004), and the full DS (22%; CI 95%, 8.6%-45.9% vs. 8%; CI 95%, 3.1%-18.0%; P=0.017) compared with group A. CONCLUSIONS: Young survivors of childhood ALL, especially those treated with cranial irradiation, are at risk for obesity, dyslipidemia, insulin resistance, hypertension, and the full DS early after the completion of therapy.
No takes yet. Share an insight, caveat, or question.
Trimis et al. (2007) conducted an observational in Acute lymphoblastic leukemia (ALL) in childhood (n=80). Chemotherapy and cranial irradiation vs. Chemotherapy only was evaluated on Full dysmetabolic syndrome (DS) (p=0.017). Childhood ALL survivors treated with chemotherapy and cranial irradiation had a higher prevalence of full dysmetabolic syndrome compared to chemotherapy alone.
Synapse has enriched 10 related papers. Consider them for comparative context: